Background In patients with type 2 diabetes, the effects ofintensive glucose control on vascular outcomes remain uncertain.
Methods We randomly assigned 11,140 patients with type 2 diabetesto undergo either standard glucose control or intensive glucosecontrol, defined as the use of gliclazide (modified release)plus other drugs as required to achieve a glycated hemoglobinvalue of 6.5% or less. Primary end points were composites ofmajor macrovascular events (death from cardiovascular causes,nonfatal myocardial infarction, or nonfatal stroke) and majormicrovascular events (new or worsening nephropathy or retinopathy),assessed both jointly and separately.
Results After a median of 5 years of follow-up, the mean glycatedhemoglobin level was lower in the intensive-control group (6.5%)than in the standard-control group (7.3%). Intensive controlreduced the incidence of combined major macrovascular and microvascularevents (18.1%, vs. 20.0% with standard control; hazard ratio,0.90; 95% confidence interval [CI], 0.82 to 0.98; P=0.01), aswell as that of major microvascular events (9.4% vs. 10.9%;hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), primarilybecause of a reduction in the incidence of nephropathy (4.1%vs. 5.2%; hazard ratio, 0.79; 95% CI, 0.66 to 0.93; P=0.006),with no significant effect on retinopathy (P=0.50). There wereno significant effects of the type of glucose control on majormacrovascular events (hazard ratio with intensive control, 0.94;95% CI, 0.84 to 1.06; P=0.32), death from cardiovascular causes(hazard ratio with intensive control, 0.88; 95% CI, 0.74 to1.04; P=0.12), or death from any cause (hazard ratio with intensivecontrol, 0.93; 95% CI, 0.83 to 1.06; P=0.28). Severe hypoglycemia,although uncommon, was more common in the intensive-controlgroup (2.7%, vs. 1.5% in the standard-control group; hazardratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001).
Conclusions A strategy of intensive glucose control, involvinggliclazide (modified release) and other drugs as required, thatlowered the glycated hemoglobin value to 6.5% yielded a 10%relative reduction in the combined outcome of major macrovascularand microvascular events, primarily as a consequence of a 21%relative reduction in nephropathy. (ClinicalTrials.gov number,NCT00145925
[ClinicalTrials.gov]
.)
Source Information
The members of the Writing Committee of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) Collaborative Group are listed in the Appendix. This article (10.1056/NEJMoa0802987) was published at www.nejm.org on June 6, 2008.
Address reprint requests to Dr. Anushka Patel at the Cardiovascular Division, George Institute for International Health, University of Sydney, P.O. Box M201, Missenden Rd., Sydney, NSW 2050, Australia, or at apatel{at}george.org.au.
Intensive Glucose Control in Type 2 Diabetes
Jenny-Avital E. R., Luan F. L., Nguyen K., Tobey T. A., Parashar A., Byington R. P., Gerstein H. C., Friedewald W. T., Patel A., MacMahon S., Chalmers J.
Extract |
Full Text |
PDF
N Engl J Med 2008;
359:1519-1521, Oct 2, 2008.
Correspondence
This article has been cited by other articles:
Lund, S. S, Tarnow, L., Frandsen, M., Nielsen, B. B, Hansen, B. V, Pedersen, O., Parving, H.-H., Vaag, A. A
(2009). Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ
339: b4324-b4324
[Abstract][Full Text]
Bertoni, A. G., Kitzman, D. W.
(2009). Coronary Artery Calcium: A Clue to the Enigma of Tight Glycemic Control and Cardiovascular Disease?. Diabetes
58: 2448-2449
[Full Text]
Zoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., Woodward, M., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial. Diabetes Care
32: 2068-2074
[Abstract][Full Text]
Reaven, P. D., Moritz, T. E., Schwenke, D. C., Anderson, R. J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., Harsha Rao, R., Shah, J. H., Goldman, S., Reda, D. J., McCarren, M., Abraira, C., Duckworth, W., for the Veterans Affairs Diabetes Trial,
(2009). Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis. Diabetes
58: 2642-2648
[Abstract][Full Text]
Bonnefond, A., Vaxillaire, M., Labrune, Y., Lecoeur, C., Chevre, J.-C., Bouatia-Naji, N., Cauchi, S., Balkau, B., Marre, M., Tichet, J., Riveline, J.-P., Hadjadj, S., Gallois, Y., Czernichow, S., Hercberg, S., Kaakinen, M., Wiesner, S., Charpentier, G., Levy-Marchal, C., Elliott, P., Jarvelin, M.-R., Horber, F., Dina, C., Pedersen, O., Sladek, R., Meyre, D., Froguel, P.
(2009). Genetic Variant in HK1 Is Associated With a Proanemic State and A1C but Not Other Glycemic Control-Related Traits. Diabetes
58: 2687-2697
[Abstract][Full Text]
Raz, I.
(2009). Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): Dilemmas in clinical practice. Diabetes Care
32: S149-S150
[Full Text]
Monnier, L., Colette, C.
(2009). Target for Glycemic Control: Concentrating on glucose. Diabetes Care
32: S199-S204
[Full Text]
Del Prato, S., Penno, G., Miccoli, R.
(2009). Changing the Treatment Paradigm for Type 2 Diabetes. Diabetes Care
32: S217-S222
[Full Text]
Bretzel, R. G., Eckhard, M., Landgraf, W., Owens, D. R., Linn, T.
(2009). Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond. Diabetes Care
32: S260-S265
[Full Text]
Gallwitz, B.
(2009). Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines. Diabetes Care
32: S322-S325
[Full Text]
Schnell, O., Otter, W., Standl, E.
(2009). The Munich Myocardial Infarction Registry: Translating the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines on diabetes, pre-diabetes, and cardiovascular disease into clinical practice. Diabetes Care
32: S326-S330
[Full Text]
Bianchi, C., Miccoli, R., Daniele, G., Penno, G., Del Prato, S.
(2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care
32: S342-S348
[Full Text]
Hanefeld, M., Bornstein, S. R., Pistrosch, F.
(2009). Shifting the Disease Management Paradigm From Glucose: What are the cons?. Diabetes Care
32: S353-S356
[Full Text]
Heller, S. R., on behalf of the ADVANCE Collaborative Group,
(2009). A Summary of the ADVANCE Trial. Diabetes Care
32: S357-S361
[Full Text]
Wilper, A. P., Woolhandler, S., Lasser, K. E., McCormick, D., Bor, D. H., Himmelstein, D. U.
(2009). Hypertension, Diabetes, And Elevated Cholesterol Among Insured And Uninsured U.S. Adults. Health Aff (Millwood)
28: w1151-w1159
[Abstract][Full Text]
Psaty, B. M., Prentice, R. L.
(2009). Variation in Event Rates in Trials of Patients With Type 2 Diabetes. JAMA
302: 1698-1700
[Full Text]
Mann, D. M., Woodward, M., Ye, F., Krousel-Wood, M., Muntner, P.
(2009). Trends in Medication Use Among US Adults With Diabetes Mellitus: Glycemic Control at the Expense of Controlling Cardiovascular Risk Factors. Arch Intern Med
169: 1718-1720
[Full Text]
Nori Janosz, K. E., Zalesin, K. C., Miller, W. M., McCullough, P. A.
(2009). Treating type 2 diabetes: incretin mimetics and enhancers. Ther Adv Cardiovasc Dis
3: 387-395
[Abstract]
Fonseca, V.
(2009). Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes. Evid. Based Med.
14: 139-139
[Full Text]
Pavkov, M. E., Mason, C. C., Bennett, P. H., Curtis, J. M., Knowler, W. C., Nelson, R. G.
(2009). Change in the Distribution of Albuminuria According to Estimated Glomerular Filtration Rate in Pima Indians With Type 2 Diabetes. Diabetes Care
32: 1845-1850
[Abstract][Full Text]
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., for the Albiglutide Study Group,
(2009). Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care
32: 1880-1886
[Abstract][Full Text]
Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J. H., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebel, R. J., Yawn, B. P., Yapuncich, V., Breslin, M. A., Pencille, L., Smith, S. A.
(2009). The Diabetes Mellitus Medication Choice Decision Aid: A Randomized Trial. Arch Intern Med
169: 1560-1568
[Abstract][Full Text]
Kosiborod, M., Inzucchi, S. E., Krumholz, H. M., Masoudi, F. A., Goyal, A., Spertus, J. A.
(2009). Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?--Reply. Arch Intern Med
169: 1637-1638
[Full Text]
Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., Ridker, P. M
(2009). Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial. JAMA
302: 1186-1194
[Abstract][Full Text]
Eggleston, K. N., Shah, N. D., Smith, S. A., Wagie, A. E., Williams, A. R., Grossman, J. H., Berndt, E. R., Long, K. H., Banerjee, R., Newhouse, J. P.
(2009). The Net Value of Health Care for Patients With Type 2 Diabetes, 1997 to 2005. ANN INTERN MED
151: 386-393
[Abstract][Full Text]
Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., He, J.
(2009). Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. ANN INTERN MED
151: 394-403
[Abstract][Full Text]
Campbell, R. K., Miller, S.
(2009). New Therapeutic Horizons: Mapping the Future of Glycemic Control With Incretin-based Therapy. The Diabetes Educator
35: 731-747
[Abstract][Full Text]
Riveline, J.-P., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., Marechaud, R., Hadjadj, S.
(2009). Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant
24: 2866-2871
[Abstract][Full Text]
Van den Berghe, G., Schetz, M., Vlasselaers, D., Hermans, G., Wilmer, A., Bouillon, R., Mesotten, D.
(2009). Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target?. J. Clin. Endocrinol. Metab.
94: 3163-3170
[Abstract][Full Text]
Potenza, M. A., Gagliardi, S., De Benedictis, L., Zigrino, A., Tiravanti, E., Colantuono, G., Federici, A., Lorusso, L., Benagiano, V., Quon, M. J., Montagnani, M.
(2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am. J. Physiol. Endocrinol. Metab.
297: E685-E694
[Abstract][Full Text]
Dhar, G. C.
(2009). Intensive glycemic control: Implications of the ACCORD, ADVANCE, and VADT trials for family physicians. cfp
55: 803-804
[Full Text]
Elley, C R., Kenealy, T.
(2009). Intensive primary care treatment reduced cardiovascular risk factors in screen-detected type 2 diabetes. Evid. Based Med.
14: 108-108
[Full Text]
Simo, R., Hernandez, C.
(2009). Advances in the Medical Treatment of Diabetic Retinopathy. Diabetes Care
32: 1556-1562
[Full Text]
Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Mogensen, C.-E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancia, G., Woodward, M., MacMahon, S., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. J. Am. Soc. Nephrol.
20: 1813-1821
[Abstract][Full Text]
Kengne, A.-P., Czernichow, S., Huxley, R., Grobbee, D., Woodward, M., Neal, B., Zoungas, S., Cooper, M., Glasziou, P., Hamet, P., Harrap, S. B., Mancia, G., Poulter, N., Williams, B., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Blood Pressure Variables and Cardiovascular Risk: New Findings From ADVANCE. Hypertension
54: 399-404
[Abstract][Full Text]
Laurent, S., Briet, M., Boutouyrie, P.
(2009). Large and Small Artery Cross-Talk and Recent Morbidity-Mortality Trials in Hypertension. Hypertension
54: 388-392
[Full Text]
(2009). How Much Evidence Do We Need to Change Practices in Which We Firmly Believe?. JWatch General
2009: 1-1
[Full Text]
Weinrauch, L. A., Lewis, E. F.
(2009). Aiming for the best control of glycemia in patients with heart failure and type 2 diabetes the "sweet spot".. J Am Coll Cardiol
54: 429-431
[Full Text]
Preis, S. R., Pencina, M. J., Hwang, S.-J., D'Agostino, R. B. Sr, Savage, P. J., Levy, D., Fox, C. S.
(2009). Trends in Cardiovascular Disease Risk Factors in Individuals With and Without Diabetes Mellitus in the Framingham Heart Study. Circulation
120: 212-220
[Abstract][Full Text]
Narendran, P.
(2009). Cardiovascular benefit of intensive glucose control: approaching closure. British Journal of Diabetes & Vascular Disease
9: 175-176
[Abstract]
Wilding, J.
(2009). Results of the LEAD-2 study in relation to NICE and ADA/EASD guidelines for the treatment of type 2 diabetes in the UK. British Journal of Diabetes & Vascular Disease
9: 177-185
[Abstract]
Chaggar, P. S., Shaw, S. M., Williams, S. G.
(2009). Review article: Thiazolidinediones and heart failure. Diabetes and Vascular Disease Research
6: 146-152
[Abstract]
Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A.
(2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol
161: 1-9
[Abstract][Full Text]
van Biesen, W., Van Laecke, S., Vanholder, R.
(2009). Treatment of type 2 diabetes in chronic kidney disease: meekly follow the herd or call to arms?. Nephrol Dial Transplant
24: 2286-2287
[Full Text]
Morath, C., Zeier, M.
(2009). Transplantation in type 1 diabetes. Nephrol Dial Transplant
24: 2026-2029
[Full Text]
Fonseca, V., Inzucchi, S. E., Ferrannini, E.
(2009). Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin. Diabetes Care
32: 1344-1345
[Full Text]
Shea, S., Weinstock, R. S., Teresi, J. A., Palmas, W., Starren, J., Cimino, J. J., Lai, A. M., Field, L., Morin, P. C., Goland, R., Izquierdo, R. E., Ebner, S., Silver, S., Petkova, E., Kong, J., Eimicke, J. P., IDEATel Consortium,
(2009). A Randomized Trial Comparing Telemedicine Case Management with Usual Care in Older, Ethnically Diverse, Medically Underserved Patients with Diabetes Mellitus: 5 Year Results of the IDEATel Study. J. Am. Med. Inform. Assoc.
16: 446-456
[Abstract][Full Text]
Cefalu, W. T.
(2009). Mortality and Glycemic Targets in the Intensive Care Unit: Another Paradigm Shift?. Diabetes
58: 1469-1470
[Full Text]
Kazempour-Ardebili, S., Lecamwasam, V. L., Dassanyake, T., Frankel, A. H., Tam, F. W.K., Dornhorst, A., Frost, G., Turner, J. J.O.
(2009). Assessing Glycemic Control in Maintenance Hemodialysis Patients With Type 2 Diabetes. Diabetes Care
32: 1137-1142
[Abstract][Full Text]
Marwick, T. H., Hordern, M. D., Miller, T., Chyun, D. A., Bertoni, A. G., Blumenthal, R. S., Philippides, G., Rocchini, A., on behalf of the American Heart Association Exerci,
(2009). Exercise Training for Type 2 Diabetes Mellitus: Impact on Cardiovascular Risk: A Scientific Statement From the American Heart Association. Circulation
119: 3244-3262
[Full Text]
The BARI 2D Study Group,
(2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM
360: 2503-2515
[Abstract][Full Text]
Montori, V. M., Fernandez-Balsells, M.
(2009). Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?. ANN INTERN MED
150: 803-808
[Abstract][Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: YES. cfp
55: 580-582
[Full Text]
Wilson, G., Perry, T.
(2009). Is tight glycemic control in type 2 diabetes really worthwhile?: NO. cfp
55: 581-583
[Full Text]
Clement, M., Bhattacharyya, O., Conway, J. R.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: OUI. cfp
55: 584-588
[Full Text]
Wilson, G., Perry, T.
(2009). Vaut-il vraiment la peine d'exercer un strict controle glycemique pour le diabete de type 2?: NON. cfp
55: 585-588
[Full Text]
Nahas, R., Moher, M.
(2009). Complementary and alternative medicine for the treatment of type 2 diabetes. cfp
55: 591-596
[Abstract][Full Text]
Haynes, R B., Haynes, G. A
(2009). What does it take to put an ugly fact through the heart of a beautiful hypothesis?. Evid. Based Med.
14: 68-69
[Full Text]
Booth, G. L
(2009). Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes. Evid. Based Med.
14: 73-73
[Full Text]
Diener, H.-C., Weimar, C.
(2009). Update of secondary stroke prevention. Nephrol Dial Transplant
24: 1718-1724
[Full Text]
Bartnik, M., Cosentino, F.
(2009). Dysglycaemia, cardiovascular outcome and treatment. Is the jury still out?. Eur Heart J
30: 1301-1304
[Full Text]
McEwen, L. N., Bilik, D., Johnson, S. L., Halter, J. B., Karter, A. J., Mangione, C. M., Subramanian, U., Waitzfelder, B., Crosson, J. C., Herman, W. H.
(2009). Predictors and Impact of Intensification of Antihyperglycemic Therapy in Type 2 Diabetes: Translating Research into Action for Diabetes (TRIAD). Diabetes Care
32: 971-976
[Abstract][Full Text]
Buse, J. B., Wolffenbuttel, B. H.R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., Martin, S. A.
(2009). DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care
32: 1007-1013
[Abstract][Full Text]
Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., Fink, J. C.
(2009). Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. CJASN
4: 1121-1127
[Abstract][Full Text]
Goode, K M, John, J, Rigby, A S, Kilpatrick, E S, Atkin, S L, Bragadeesh, T, Clark, A L, Cleland, J G F
(2009). Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus. Heart
95: 917-923
[Abstract][Full Text]
Senador, D., Kanakamedala, K., Irigoyen, M. C., Morris, M., Elased, K. M.
(2009). Cardiovascular and autonomic phenotype of db/db diabetic mice. Exp Physiol
94: 648-658
[Abstract][Full Text]
Griffin, S., Graffy, J.
(2009). New QOF glycaemia targets are achievable and evidence based. BMJ
338: b1915-b1915
[Full Text]
Gellad, W. F., Detsky, A. S., Choudhry, N. K.
(2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm
66: 864-867
[Full Text]
Verhaert, D., Thomas, J. D.
(2009). Dysglycemia and acute myocardial infarction the role of echocardiography.. J Am Coll Cardiol Img
2: 600-603
[Full Text]
Parving, H.-H., Brenner, B. M., McMurray, John. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Ghadanfar, M., Weissbach, N., Xiang, Z., Armbrecht, J., Pfeffer, M. A.
(2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant
24: 1663-1671
[Abstract][Full Text]
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K., Calkin, A. C., Brownlee, M., Cooper, M. E., El-Osta, A.
(2009). Hyperglycemia Induces a Dynamic Cooperativity of Histone Methylase and Demethylase Enzymes Associated With Gene-Activating Epigenetic Marks That Coexist on the Lysine Tail. Diabetes
58: 1229-1236
[Abstract][Full Text]
Brice, R.
(2009). A taxi driver with type 2 diabetes. BMJ
338: b1369-b1369
[Full Text]
Cheng, A. Y.Y., Leiter, L. A.
(2009). Cardiovascular risk and glycemic control. CMAJ
180: 907-908
[Full Text]
Kahn, S. E.
(2009). Glucose Control in Type 2 Diabetes: Still Worthwhile and Worth Pursuing. JAMA
301: 1590-1592
[Full Text]
Nathan, D. M.
(2009). Progress in Diabetes Research--What's Next. JAMA
301: 1599-1601
[Full Text]
Sanz, J., Moreno, P. R., Fuster, V.
(2009). The year in atherothrombosis.. J Am Coll Cardiol
53: 1326-1337
[Full Text]
Van den Berghe, G., Mesotten, D., Vanhorebeek, I.
(2009). Intensive insulin therapy in the intensive care unit. CMAJ
180: 799-800
[Full Text]
Preis, S. R., Hwang, S.-J., Coady, S., Pencina, M. J., D'Agostino, R. B. Sr, Savage, P. J., Levy, D., Fox, C. S.
(2009). Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005. Circulation
119: 1728-1735
[Abstract][Full Text]
Olin, J. L., Spooner, L. M.
(2009). Introduction: Cardiovascular Therapeutics. Journal of Pharmacy Practice
22: 133-134
Sherifali, D., Punthakee, Z.
(2009). To lower or not to lower? Making sense of the latest research on intensive glycaemic control and cardiovascular outcomes. Evid. Based Med.
14: 34-37
[Full Text]
Cochran, E.
(2009). U-500 Insulin: When More With Less Yields Success. Diabetes Spectr.
22: 116-122
[Full Text]
O'Connor, P. J., Sperl-Hillen, J. M.
(2009). The Role of Diabetes Educators in the Medical Home. Diabetes Spectr.
22: 124-126
[Full Text]
Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D.
(2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice
22: 179-193
[Abstract]
Nuzum, D. S., Merz, T.
(2009). Macrovascular Complications of Diabetes Mellitus. Journal of Pharmacy Practice
22: 135-148
[Abstract]
Younis, N., Soran, H., Hassanein, M.
(2009). Cardiovascular disease and intensive glucose lowering in type 2 diabetes. QJM
102: 293-296
[Full Text]
de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C.-E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancia, G., Woodward, M., Glasziou, P., Grobbee, D. E., MacMahon, S., Chalmers, J., on behalf of the ADVANCE Collaborative Group,
(2009). Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. J. Am. Soc. Nephrol.
20: 883-892
[Abstract][Full Text]
Chait, A., Bornfeldt, K. E.
(2009). Diabetes and atherosclerosis: is there a role for hyperglycemia?. J. Lipid Res.
50: S335-S339
[Abstract][Full Text]
The NICE-SUGAR Study Investigators,
(2009). Intensive versus Conventional Glucose Control in Critically Ill Patients. NEJM
360: 1283-1297
[Abstract][Full Text]
Kosiborod, M., Inzucchi, S. E., Krumholz, H. M., Masoudi, F. A., Goyal, A., Xiao, L., Jones, P. G., Fiske, S., Spertus, J. A.
(2009). Glucose Normalization and Outcomes in Patients With Acute Myocardial Infarction. Arch Intern Med
169: 438-446
[Abstract][Full Text]
Lehman, R., Krumholz, H. M
(2009). Tight control of blood glucose in long standing type 2 diabetes. BMJ
338: b800-b800
[Full Text]
Song, S. H, Gray, T. A
(2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease
9: 69-74
[Abstract]
Henske, J. A., Griffith, M. L., Fowler, M. J.
(2009). Initiating and Titrating Insulin in Patients With Type 2 Diabetes. Clin. Diabetes
27: 72-76
[Full Text]
Raz, I., Wilson, P. W.F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., Jacober, S. J.
(2009). Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care
32: 381-386
[Abstract][Full Text]
Previous
